June 11, 2021 10:08 AM EDTUpdated 10:21 AM

Intercept retools C-suite with a pair of newcomers; Charles Ryan moves past Alzheimer's flops with another CEO challenge

Alex Hoffman

Copy Chief

Kathy Wong

Editor

→ Jason Campagna and Sandip Kapadia were two execs who punched their tickets out of Intercept as things went pear-shaped, and the teetering NASH biotech …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Intercept retools C-suite with a pair of newcomers; Charles Ryan moves past Alzheimer's flops with another CEO challenge

Alex Hoffman

Copy Chief

Kathy Wong

Editor

Sign up to read this article for free.

New fund will pressure flailing biotechs, as investor frustration boils over

FDA chief Makary talks expediting drug approvals, RIFs and the abortion pill

Akeso shares new data suggesting it can beat Keytruda on survival, wins China approval

J&J reports durability data for bladder cancer 'pretzel' drug after FDA filing

AbbVie commits $10B to expand US footprint with the threat of tariffs ahead

ADSTILADRIN® (nadofaragene firadenovec-vncg) – A Growing Body of Clinical Data and Real-World Evidence

In­ter­cept re­tools C-suite with a pair of new­com­ers; Charles Ryan moves past Alzheimer's flops with an­oth­er CEO chal­lenge

Copy Chief

Editor

Sign up to read this article for free.

Intercept retools C-suite with a pair of newcomers; Charles Ryan moves past Alzheimer's flops with another CEO challenge